The U.S. District Court for the Southern District of Ohio recently held that New Jersey law bars punitive damages for prescription pharmaceuticals that are approved by the FDA.
The U.S. Supreme Court invited the U.S. solicitor general's comments on petition to review a Ninth Circuit decision expanding jurisdiction under the Foreign Sovereign Immunities Act.
The court recently addressed the ever-present question of FDA preemption of state-law pharmaceutical claims, specifically those arising under Texas law.
By David L. Schwan
The revised rule clears up much confusion.
By Timothy S. Tomasik and Patrick J. Giese
Addressing the admissibility of government reports under Federal Rule of Evidence 803(8)(A)(iii) in the context of aviation litigation.
By Andrew J. Scholz
New York stands out as one of the most difficult jurisdictions for defendants and their insurers.
Veteran litigator Douglas Maag details how U.S. economic and trade sanctions can affect the handling of mass-tort claims. (8:13 min)
Examining the holding in this newly announced decision and what it may mean for future parens patriae actions and other types of quasi-class actions or mass actions. (56:12)
Featuring a unique group of lawyers and non-lawyers to provide a fact-based peek into the future, including presentations and an interactive discussion among the panelists. (1:01:42)
Learn about the significance of the Barltett decision and its impact on the Supreme Court's preemption holdings. (57:33)
The latest edition of Mass Torts is now available.
Mass Torts Leadership
|Cochairs||Web Editor||Newsletter Editor|
New York, NY
Kansas City, MO
Leadership Development & Young Lawyer Outreach Liaison
Sun Valley, CA